ras homolog family member JGenealiases: ARHJ · RASL7B · TC10B · TCL
Q-omics provides the consensus-scored RHOJ profile across patient tissues and cancer cell-line models. RHOJ expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RHOJ is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, RHOJ RNA expression shows 24,120 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, BLCA, and LSCC as cancer lineages where RHOJ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHOJ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHOJ survival associations across molecular data types. RHOJ RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHOJ RNA expression–survival associations across cancer types. High RHOJ expression shows unfavorable associations in KIRP, BLCA, MESO, LGG and LUSC, but favorable associations in HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RHOJ RNA expression.
This table summarizes RHOJ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RHOJ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHOJ shows lower tumor expression in BLCA, LUAD, THCA, LUSC and KICH and higher tumor expression in KIRC. The BLCA box plot shows higher RHOJ RNA expression in normal versus tumor tissue (log2 FC = −2.547, t-test p < 0.001).
This table shows molecular features associated with RHOJ in patient tissues and cancer cell lines. In patient samples, RHOJ shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RHOJ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
